JP2013529292A - 緑内障の診断方法 - Google Patents
緑内障の診断方法 Download PDFInfo
- Publication number
- JP2013529292A JP2013529292A JP2013504084A JP2013504084A JP2013529292A JP 2013529292 A JP2013529292 A JP 2013529292A JP 2013504084 A JP2013504084 A JP 2013504084A JP 2013504084 A JP2013504084 A JP 2013504084A JP 2013529292 A JP2013529292 A JP 2013529292A
- Authority
- JP
- Japan
- Prior art keywords
- antigen
- glaucoma
- antigens
- protein
- sample
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 208000010412 Glaucoma Diseases 0.000 title claims abstract description 270
- 239000000427 antigen Substances 0.000 claims abstract description 360
- 102000036639 antigens Human genes 0.000 claims abstract description 360
- 108091007433 antigens Proteins 0.000 claims abstract description 360
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 191
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 187
- 238000000034 method Methods 0.000 claims abstract description 130
- 230000009257 reactivity Effects 0.000 claims abstract description 101
- 210000001124 body fluid Anatomy 0.000 claims abstract description 95
- 239000010839 body fluid Substances 0.000 claims abstract description 77
- 230000001363 autoimmune Effects 0.000 claims abstract description 70
- 238000002405 diagnostic procedure Methods 0.000 claims abstract description 53
- 238000004458 analytical method Methods 0.000 claims abstract description 52
- 238000012360 testing method Methods 0.000 claims abstract description 49
- 238000011282 treatment Methods 0.000 claims abstract description 34
- 238000003745 diagnosis Methods 0.000 claims abstract description 19
- 238000000338 in vitro Methods 0.000 claims abstract description 15
- 230000003833 cell viability Effects 0.000 claims abstract description 14
- 210000004027 cell Anatomy 0.000 claims description 170
- 210000002966 serum Anatomy 0.000 claims description 147
- 239000000523 sample Substances 0.000 claims description 108
- 239000000090 biomarker Substances 0.000 claims description 53
- 238000002493 microarray Methods 0.000 claims description 31
- 238000010195 expression analysis Methods 0.000 claims description 27
- 108010071690 Prealbumin Proteins 0.000 claims description 25
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 claims description 25
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 claims description 25
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 claims description 25
- 102000004121 Annexin A5 Human genes 0.000 claims description 22
- 108090000672 Annexin A5 Proteins 0.000 claims description 22
- 230000000694 effects Effects 0.000 claims description 22
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims description 22
- -1 jo-1 Proteins 0.000 claims description 22
- 230000035899 viability Effects 0.000 claims description 22
- 210000003994 retinal ganglion cell Anatomy 0.000 claims description 21
- 102000015395 alpha 1-Antitrypsin Human genes 0.000 claims description 20
- 108010050122 alpha 1-Antitrypsin Proteins 0.000 claims description 20
- 229940024142 alpha 1-antitrypsin Drugs 0.000 claims description 20
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 20
- 102000002233 Myelin-Oligodendrocyte Glycoprotein Human genes 0.000 claims description 19
- 108010000123 Myelin-Oligodendrocyte Glycoprotein Proteins 0.000 claims description 19
- 108090000099 Neurotrophin-4 Proteins 0.000 claims description 19
- 108010045100 HSP27 Heat-Shock Proteins Proteins 0.000 claims description 18
- 108010022181 Phosphopyruvate Hydratase Proteins 0.000 claims description 18
- 102000012288 Phosphopyruvate Hydratase Human genes 0.000 claims description 18
- 101710163595 Chaperone protein DnaK Proteins 0.000 claims description 17
- 101710178376 Heat shock 70 kDa protein Proteins 0.000 claims description 17
- 101710152018 Heat shock cognate 70 kDa protein Proteins 0.000 claims description 17
- 102100039165 Heat shock protein beta-1 Human genes 0.000 claims description 17
- 102000009190 Transthyretin Human genes 0.000 claims description 17
- 102000044159 Ubiquitin Human genes 0.000 claims description 17
- 108090000848 Ubiquitin Proteins 0.000 claims description 17
- 102000004219 Brain-derived neurotrophic factor Human genes 0.000 claims description 16
- 108090000715 Brain-derived neurotrophic factor Proteins 0.000 claims description 16
- 239000000463 material Substances 0.000 claims description 16
- 102000007469 Actins Human genes 0.000 claims description 15
- 102000004963 gamma-Synuclein Human genes 0.000 claims description 15
- 108090001121 gamma-Synuclein Proteins 0.000 claims description 15
- 101710175516 14 kDa zinc-binding protein Proteins 0.000 claims description 14
- 102100038222 60 kDa heat shock protein, mitochondrial Human genes 0.000 claims description 14
- 108010085238 Actins Proteins 0.000 claims description 14
- 108010058432 Chaperonin 60 Proteins 0.000 claims description 14
- 229940123924 Protein kinase C inhibitor Drugs 0.000 claims description 14
- 230000006907 apoptotic process Effects 0.000 claims description 14
- 239000003881 protein kinase C inhibitor Substances 0.000 claims description 14
- 102000019197 Superoxide Dismutase Human genes 0.000 claims description 13
- 108010012715 Superoxide dismutase Proteins 0.000 claims description 13
- 102000004338 Transferrin Human genes 0.000 claims description 13
- 108090000901 Transferrin Proteins 0.000 claims description 13
- 102000013069 gamma-Crystallins Human genes 0.000 claims description 13
- 108010079934 gamma-Crystallins Proteins 0.000 claims description 13
- 239000012581 transferrin Substances 0.000 claims description 13
- 102000009027 Albumins Human genes 0.000 claims description 12
- 108010088751 Albumins Proteins 0.000 claims description 12
- 102000000412 Annexin Human genes 0.000 claims description 12
- 108050008874 Annexin Proteins 0.000 claims description 12
- 108010059013 Chaperonin 10 Proteins 0.000 claims description 12
- 108050001186 Chaperonin Cpn60 Proteins 0.000 claims description 12
- 102000052603 Chaperonins Human genes 0.000 claims description 12
- 101710119265 DNA topoisomerase 1 Proteins 0.000 claims description 12
- 102100024607 DNA topoisomerase 1 Human genes 0.000 claims description 12
- 102000005720 Glutathione transferase Human genes 0.000 claims description 12
- 108010070675 Glutathione transferase Proteins 0.000 claims description 12
- 102000004877 Insulin Human genes 0.000 claims description 12
- 108090001061 Insulin Proteins 0.000 claims description 12
- 108010014499 beta-2 Adrenergic Receptors Proteins 0.000 claims description 12
- 102000016966 beta-2 Adrenergic Receptors Human genes 0.000 claims description 12
- 229940077737 brain-derived neurotrophic factor Drugs 0.000 claims description 12
- 238000004113 cell culture Methods 0.000 claims description 12
- 238000010324 immunological assay Methods 0.000 claims description 12
- 150000002978 peroxides Chemical class 0.000 claims description 12
- 238000012545 processing Methods 0.000 claims description 12
- 102000004082 Calreticulin Human genes 0.000 claims description 11
- 108090000549 Calreticulin Proteins 0.000 claims description 11
- 102000014914 Carrier Proteins Human genes 0.000 claims description 11
- 108010067306 Fibronectins Proteins 0.000 claims description 11
- 102000016359 Fibronectins Human genes 0.000 claims description 11
- 102000006386 Myelin Proteins Human genes 0.000 claims description 11
- 108010083674 Myelin Proteins Proteins 0.000 claims description 11
- 102000003923 Protein Kinase C Human genes 0.000 claims description 11
- 108090000315 Protein Kinase C Proteins 0.000 claims description 11
- 102000013640 alpha-Crystallin B Chain Human genes 0.000 claims description 11
- 108010051585 alpha-Crystallin B Chain Proteins 0.000 claims description 11
- 102000003802 alpha-Synuclein Human genes 0.000 claims description 11
- 108090000185 alpha-Synuclein Proteins 0.000 claims description 11
- 108091008324 binding proteins Proteins 0.000 claims description 11
- 229940125396 insulin Drugs 0.000 claims description 11
- 210000005012 myelin Anatomy 0.000 claims description 11
- 102000053171 Glial Fibrillary Acidic Human genes 0.000 claims description 10
- 101710193519 Glial fibrillary acidic protein Proteins 0.000 claims description 10
- 102000016943 Muramidase Human genes 0.000 claims description 10
- 108010014251 Muramidase Proteins 0.000 claims description 10
- 108010062374 Myoglobin Proteins 0.000 claims description 10
- 102000036675 Myoglobin Human genes 0.000 claims description 10
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 claims description 10
- 108090000742 Neurotrophin 3 Proteins 0.000 claims description 10
- 102000004230 Neurotrophin 3 Human genes 0.000 claims description 10
- 102000003683 Neurotrophin-4 Human genes 0.000 claims description 10
- 102000005890 Spectrin Human genes 0.000 claims description 10
- 108010019965 Spectrin Proteins 0.000 claims description 10
- 102100031874 Spectrin alpha chain, non-erythrocytic 1 Human genes 0.000 claims description 10
- 108010065472 Vimentin Proteins 0.000 claims description 10
- 108010055905 alpha-Crystallin A Chain Proteins 0.000 claims description 10
- 238000004422 calculation algorithm Methods 0.000 claims description 10
- 238000006243 chemical reaction Methods 0.000 claims description 10
- ZGSPNIOCEDOHGS-UHFFFAOYSA-L disodium [3-[2,3-di(octadeca-9,12-dienoyloxy)propoxy-oxidophosphoryl]oxy-2-hydroxypropyl] 2,3-di(octadeca-9,12-dienoyloxy)propyl phosphate Chemical compound [Na+].[Na+].CCCCCC=CCC=CCCCCCCCC(=O)OCC(OC(=O)CCCCCCCC=CCC=CCCCCC)COP([O-])(=O)OCC(O)COP([O-])(=O)OCC(OC(=O)CCCCCCCC=CCC=CCCCCC)COC(=O)CCCCCCCC=CCC=CCCCCC ZGSPNIOCEDOHGS-UHFFFAOYSA-L 0.000 claims description 10
- 239000003534 dna topoisomerase inhibitor Substances 0.000 claims description 10
- 238000002474 experimental method Methods 0.000 claims description 10
- 108010006620 fodrin Proteins 0.000 claims description 10
- 210000005046 glial fibrillary acidic protein Anatomy 0.000 claims description 10
- 238000012125 lateral flow test Methods 0.000 claims description 10
- 229960000274 lysozyme Drugs 0.000 claims description 10
- 235000010335 lysozyme Nutrition 0.000 claims description 10
- 239000004325 lysozyme Substances 0.000 claims description 10
- 239000000203 mixture Substances 0.000 claims description 10
- 229940032018 neurotrophin 3 Drugs 0.000 claims description 10
- 229940097998 neurotrophin 4 Drugs 0.000 claims description 10
- BZQFBWGGLXLEPQ-REOHCLBHSA-N phosphoserine Chemical compound OC(=O)[C@@H](N)COP(O)(O)=O BZQFBWGGLXLEPQ-REOHCLBHSA-N 0.000 claims description 10
- 229940044693 topoisomerase inhibitor Drugs 0.000 claims description 10
- 210000005048 vimentin Anatomy 0.000 claims description 10
- 102100033857 Neurotrophin-4 Human genes 0.000 claims description 9
- 238000003556 assay Methods 0.000 claims description 9
- 238000004949 mass spectrometry Methods 0.000 claims description 9
- 238000012544 monitoring process Methods 0.000 claims description 9
- 208000015122 neurodegenerative disease Diseases 0.000 claims description 9
- 102100029290 Transthyretin Human genes 0.000 claims description 8
- 239000003463 adsorbent Substances 0.000 claims description 8
- 230000004770 neurodegeneration Effects 0.000 claims description 8
- 230000001225 therapeutic effect Effects 0.000 claims description 7
- 208000023275 Autoimmune disease Diseases 0.000 claims description 6
- 230000001413 cellular effect Effects 0.000 claims description 6
- 239000000376 reactant Substances 0.000 claims description 6
- 102000009843 Thyroglobulin Human genes 0.000 claims description 5
- 108010034949 Thyroglobulin Proteins 0.000 claims description 5
- 238000002372 labelling Methods 0.000 claims description 5
- 230000008569 process Effects 0.000 claims description 5
- 229960002175 thyroglobulin Drugs 0.000 claims description 5
- 206010061818 Disease progression Diseases 0.000 claims description 4
- 102000004190 Enzymes Human genes 0.000 claims description 4
- 108090000790 Enzymes Proteins 0.000 claims description 4
- 108050001049 Extracellular proteins Proteins 0.000 claims description 4
- 102000006395 Globulins Human genes 0.000 claims description 4
- 108010044091 Globulins Proteins 0.000 claims description 4
- 230000005750 disease progression Effects 0.000 claims description 4
- 229940088598 enzyme Drugs 0.000 claims description 4
- 238000012606 in vitro cell culture Methods 0.000 claims description 4
- 238000011065 in-situ storage Methods 0.000 claims description 4
- 210000004498 neuroglial cell Anatomy 0.000 claims description 4
- 210000001164 retinal progenitor cell Anatomy 0.000 claims description 4
- 238000001262 western blot Methods 0.000 claims description 4
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 claims description 3
- 238000001840 matrix-assisted laser desorption--ionisation time-of-flight mass spectrometry Methods 0.000 claims description 3
- 238000001742 protein purification Methods 0.000 claims description 3
- 238000010186 staining Methods 0.000 claims description 3
- 101800000263 Acidic protein Proteins 0.000 claims description 2
- 102000019355 Synuclein Human genes 0.000 claims description 2
- 108050006783 Synuclein Proteins 0.000 claims description 2
- 230000015556 catabolic process Effects 0.000 claims description 2
- 238000006731 degradation reaction Methods 0.000 claims description 2
- 238000000684 flow cytometry Methods 0.000 claims description 2
- 238000005194 fractionation Methods 0.000 claims description 2
- 230000003834 intracellular effect Effects 0.000 claims description 2
- 230000013777 protein digestion Effects 0.000 claims description 2
- 238000000926 separation method Methods 0.000 claims description 2
- 239000000758 substrate Substances 0.000 claims description 2
- 238000000672 surface-enhanced laser desorption--ionisation Methods 0.000 claims description 2
- 125000003831 tetrazolyl group Chemical group 0.000 claims description 2
- 102000013127 Vimentin Human genes 0.000 claims 3
- 108091000080 Phosphotransferase Proteins 0.000 claims 1
- 239000002250 absorbent Substances 0.000 claims 1
- 230000002745 absorbent Effects 0.000 claims 1
- 102000020233 phosphotransferase Human genes 0.000 claims 1
- ZDWVWKDAWBGPDN-UHFFFAOYSA-O propidium Chemical compound C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CCC[N+](C)(CC)CC)=C1C1=CC=CC=C1 ZDWVWKDAWBGPDN-UHFFFAOYSA-O 0.000 claims 1
- 238000011084 recovery Methods 0.000 claims 1
- 230000006870 function Effects 0.000 abstract description 7
- 239000003550 marker Substances 0.000 abstract description 4
- 239000008194 pharmaceutical composition Substances 0.000 abstract description 3
- 230000006472 autoimmune response Effects 0.000 abstract description 2
- 206010030348 Open-Angle Glaucoma Diseases 0.000 description 82
- 201000006366 primary open angle glaucoma Diseases 0.000 description 82
- 210000001742 aqueous humor Anatomy 0.000 description 54
- 230000001965 increasing effect Effects 0.000 description 29
- 230000035945 sensitivity Effects 0.000 description 19
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 18
- 230000004410 intraocular pressure Effects 0.000 description 18
- 238000013528 artificial neural network Methods 0.000 description 17
- 238000001514 detection method Methods 0.000 description 16
- 238000011534 incubation Methods 0.000 description 14
- 239000002953 phosphate buffered saline Substances 0.000 description 14
- 108010033040 Histones Proteins 0.000 description 11
- 206010067013 Normal tension glaucoma Diseases 0.000 description 11
- 201000002978 low tension glaucoma Diseases 0.000 description 11
- 239000011324 bead Substances 0.000 description 10
- 238000004364 calculation method Methods 0.000 description 10
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 9
- 206010030043 Ocular hypertension Diseases 0.000 description 9
- 239000013592 cell lysate Substances 0.000 description 9
- 230000000875 corresponding effect Effects 0.000 description 9
- 201000010099 disease Diseases 0.000 description 9
- 239000012530 fluid Substances 0.000 description 9
- 238000011160 research Methods 0.000 description 9
- 230000002207 retinal effect Effects 0.000 description 9
- 238000000540 analysis of variance Methods 0.000 description 8
- 230000008901 benefit Effects 0.000 description 8
- 238000005259 measurement Methods 0.000 description 8
- 239000000243 solution Substances 0.000 description 8
- 102000004899 14-3-3 Proteins Human genes 0.000 description 7
- 241000282414 Homo sapiens Species 0.000 description 7
- 101000723543 Homo sapiens 14-3-3 protein theta Proteins 0.000 description 7
- 239000000020 Nitrocellulose Substances 0.000 description 7
- 102100035071 Vimentin Human genes 0.000 description 7
- 230000030833 cell death Effects 0.000 description 7
- 230000004406 elevated intraocular pressure Effects 0.000 description 7
- 239000000499 gel Substances 0.000 description 7
- 229920001220 nitrocellulos Polymers 0.000 description 7
- 238000007619 statistical method Methods 0.000 description 7
- 238000012800 visualization Methods 0.000 description 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- 230000027455 binding Effects 0.000 description 6
- 239000000872 buffer Substances 0.000 description 6
- 238000002508 contact lithography Methods 0.000 description 6
- 239000011159 matrix material Substances 0.000 description 6
- 108090000765 processed proteins & peptides Proteins 0.000 description 6
- 230000001105 regulatory effect Effects 0.000 description 6
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 5
- 102000006947 Histones Human genes 0.000 description 5
- 238000013459 approach Methods 0.000 description 5
- 238000003570 cell viability assay Methods 0.000 description 5
- 230000003247 decreasing effect Effects 0.000 description 5
- HKSZLNNOFSGOKW-UHFFFAOYSA-N ent-staurosporine Natural products C12=C3N4C5=CC=CC=C5C3=C3CNC(=O)C3=C2C2=CC=CC=C2N1C1CC(NC)C(OC)C4(C)O1 HKSZLNNOFSGOKW-UHFFFAOYSA-N 0.000 description 5
- 239000002609 medium Substances 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- HKSZLNNOFSGOKW-FYTWVXJKSA-N staurosporine Chemical compound C12=C3N4C5=CC=CC=C5C3=C3CNC(=O)C3=C2C2=CC=CC=C2N1[C@H]1C[C@@H](NC)[C@@H](OC)[C@]4(C)O1 HKSZLNNOFSGOKW-FYTWVXJKSA-N 0.000 description 5
- CGPUWJWCVCFERF-UHFFFAOYSA-N staurosporine Natural products C12=C3N4C5=CC=CC=C5C3=C3CNC(=O)C3=C2C2=CC=CC=C2N1C1CC(NC)C(OC)C4(OC)O1 CGPUWJWCVCFERF-UHFFFAOYSA-N 0.000 description 5
- 238000005406 washing Methods 0.000 description 5
- 238000002965 ELISA Methods 0.000 description 4
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 4
- 102000004142 Trypsin Human genes 0.000 description 4
- 108090000631 Trypsin Proteins 0.000 description 4
- 230000010261 cell growth Effects 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 239000012091 fetal bovine serum Substances 0.000 description 4
- 238000004128 high performance liquid chromatography Methods 0.000 description 4
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 4
- 238000010606 normalization Methods 0.000 description 4
- 238000001556 precipitation Methods 0.000 description 4
- 230000004044 response Effects 0.000 description 4
- 238000012216 screening Methods 0.000 description 4
- 238000000756 surface-enhanced laser desorption--ionisation time-of-flight mass spectrometry Methods 0.000 description 4
- 239000012588 trypsin Substances 0.000 description 4
- 230000000007 visual effect Effects 0.000 description 4
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- 201000004569 Blindness Diseases 0.000 description 3
- 208000002177 Cataract Diseases 0.000 description 3
- 102100034523 Histone H4 Human genes 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 239000012298 atmosphere Substances 0.000 description 3
- 210000004556 brain Anatomy 0.000 description 3
- 239000013078 crystal Substances 0.000 description 3
- 210000004292 cytoskeleton Anatomy 0.000 description 3
- 238000003795 desorption Methods 0.000 description 3
- 238000010586 diagram Methods 0.000 description 3
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 3
- 230000002255 enzymatic effect Effects 0.000 description 3
- 208000030533 eye disease Diseases 0.000 description 3
- 125000000524 functional group Chemical group 0.000 description 3
- 239000011521 glass Substances 0.000 description 3
- 230000002706 hydrostatic effect Effects 0.000 description 3
- 239000012139 lysis buffer Substances 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 230000001537 neural effect Effects 0.000 description 3
- 210000001328 optic nerve Anatomy 0.000 description 3
- 230000003287 optical effect Effects 0.000 description 3
- 239000008188 pellet Substances 0.000 description 3
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 3
- 230000000750 progressive effect Effects 0.000 description 3
- 238000003498 protein array Methods 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- PCMORTLOPMLEFB-ONEGZZNKSA-N sinapic acid Chemical compound COC1=CC(\C=C\C(O)=O)=CC(OC)=C1O PCMORTLOPMLEFB-ONEGZZNKSA-N 0.000 description 3
- PCMORTLOPMLEFB-UHFFFAOYSA-N sinapinic acid Natural products COC1=CC(C=CC(O)=O)=CC(OC)=C1O PCMORTLOPMLEFB-UHFFFAOYSA-N 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 210000001138 tear Anatomy 0.000 description 3
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 2
- 241000283707 Capra Species 0.000 description 2
- 108060003951 Immunoglobulin Proteins 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 208000018737 Parkinson disease Diseases 0.000 description 2
- 108010033276 Peptide Fragments Proteins 0.000 description 2
- 102000007079 Peptide Fragments Human genes 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- 101710120037 Toxin CcdB Proteins 0.000 description 2
- 241000364021 Tulsa Species 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 238000007792 addition Methods 0.000 description 2
- 238000003491 array Methods 0.000 description 2
- 230000008827 biological function Effects 0.000 description 2
- OWMVSZAMULFTJU-UHFFFAOYSA-N bis-tris Chemical compound OCCN(CCO)C(CO)(CO)CO OWMVSZAMULFTJU-UHFFFAOYSA-N 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 230000003828 downregulation Effects 0.000 description 2
- 235000019253 formic acid Nutrition 0.000 description 2
- 230000008014 freezing Effects 0.000 description 2
- 238000007710 freezing Methods 0.000 description 2
- 238000001502 gel electrophoresis Methods 0.000 description 2
- 230000002518 glial effect Effects 0.000 description 2
- 102000018358 immunoglobulin Human genes 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 230000002427 irreversible effect Effects 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 230000017074 necrotic cell death Effects 0.000 description 2
- 210000000653 nervous system Anatomy 0.000 description 2
- 210000002569 neuron Anatomy 0.000 description 2
- 238000001543 one-way ANOVA Methods 0.000 description 2
- 238000012014 optical coherence tomography Methods 0.000 description 2
- 230000036961 partial effect Effects 0.000 description 2
- 230000002093 peripheral effect Effects 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 238000003127 radioimmunoassay Methods 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000003938 response to stress Effects 0.000 description 2
- 210000003296 saliva Anatomy 0.000 description 2
- 238000010561 standard procedure Methods 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 238000001269 time-of-flight mass spectrometry Methods 0.000 description 2
- 230000009466 transformation Effects 0.000 description 2
- 230000003827 upregulation Effects 0.000 description 2
- 230000028973 vesicle-mediated transport Effects 0.000 description 2
- 230000004393 visual impairment Effects 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 1
- NGZXDRGWBULKFA-NSOVKSMOSA-N (+)-Bebeerine Chemical compound C([C@@H]1N(C)CCC=2C=C(C(=C(OC3=CC=C(C=C3)C[C@H]3C=4C=C(C(=CC=4CCN3C)OC)O3)C=21)O)OC)C1=CC=C(O)C3=C1 NGZXDRGWBULKFA-NSOVKSMOSA-N 0.000 description 1
- WBYWAXJHAXSJNI-VOTSOKGWSA-M .beta-Phenylacrylic acid Natural products [O-]C(=O)\C=C\C1=CC=CC=C1 WBYWAXJHAXSJNI-VOTSOKGWSA-M 0.000 description 1
- KISWVXRQTGLFGD-UHFFFAOYSA-N 2-[[2-[[6-amino-2-[[2-[[2-[[5-amino-2-[[2-[[1-[2-[[6-amino-2-[(2,5-diamino-5-oxopentanoyl)amino]hexanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]pyrrolidine-2-carbonyl]amino]-3-hydroxypropanoyl]amino]-5-oxopentanoyl]amino]-5-(diaminomethylideneamino)p Chemical compound C1CCN(C(=O)C(CCCN=C(N)N)NC(=O)C(CCCCN)NC(=O)C(N)CCC(N)=O)C1C(=O)NC(CO)C(=O)NC(CCC(N)=O)C(=O)NC(CCCN=C(N)N)C(=O)NC(CO)C(=O)NC(CCCCN)C(=O)NC(C(=O)NC(CC(C)C)C(O)=O)CC1=CC=C(O)C=C1 KISWVXRQTGLFGD-UHFFFAOYSA-N 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 206010003694 Atrophy Diseases 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 102000016078 Chaperonin Containing TCP-1 Human genes 0.000 description 1
- 108010010706 Chaperonin Containing TCP-1 Proteins 0.000 description 1
- WBYWAXJHAXSJNI-SREVYHEPSA-N Cinnamic acid Chemical compound OC(=O)\C=C/C1=CC=CC=C1 WBYWAXJHAXSJNI-SREVYHEPSA-N 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 102000010831 Cytoskeletal Proteins Human genes 0.000 description 1
- 108010037414 Cytoskeletal Proteins Proteins 0.000 description 1
- SNRUBQQJIBEYMU-UHFFFAOYSA-N Dodecane Natural products CCCCCCCCCCCC SNRUBQQJIBEYMU-UHFFFAOYSA-N 0.000 description 1
- 108090000386 Fibroblast Growth Factor 1 Proteins 0.000 description 1
- 102100031706 Fibroblast growth factor 1 Human genes 0.000 description 1
- 240000008168 Ficus benjamina Species 0.000 description 1
- 102000013366 Filamin Human genes 0.000 description 1
- 108060002900 Filamin Proteins 0.000 description 1
- 208000003098 Ganglion Cysts Diseases 0.000 description 1
- 229920002683 Glycosaminoglycan Polymers 0.000 description 1
- 101000617823 Homo sapiens Solute carrier organic anion transporter family member 6A1 Proteins 0.000 description 1
- 101000621427 Homo sapiens Wiskott-Aldrich syndrome protein Proteins 0.000 description 1
- 102000002151 Microfilament Proteins Human genes 0.000 description 1
- 108010025020 Nerve Growth Factor Proteins 0.000 description 1
- 102000007072 Nerve Growth Factors Human genes 0.000 description 1
- 208000028389 Nerve injury Diseases 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 208000025966 Neurological disease Diseases 0.000 description 1
- 108010047956 Nucleosomes Proteins 0.000 description 1
- 241000238413 Octopus Species 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 102000010292 Peptide Elongation Factor 1 Human genes 0.000 description 1
- 108010077524 Peptide Elongation Factor 1 Proteins 0.000 description 1
- 102000011755 Phosphoglycerate Kinase Human genes 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 241000700157 Rattus norvegicus Species 0.000 description 1
- PLXBWHJQWKZRKG-UHFFFAOYSA-N Resazurin Chemical compound C1=CC(=O)C=C2OC3=CC(O)=CC=C3[N+]([O-])=C21 PLXBWHJQWKZRKG-UHFFFAOYSA-N 0.000 description 1
- 239000011542 SDS running buffer Substances 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 102100021991 Solute carrier organic anion transporter family member 6A1 Human genes 0.000 description 1
- 101000874347 Streptococcus agalactiae IgA FC receptor Proteins 0.000 description 1
- 208000005400 Synovial Cyst Diseases 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 101001099217 Thermotoga maritima (strain ATCC 43589 / DSM 3109 / JCM 10099 / NBRC 100826 / MSB8) Triosephosphate isomerase Proteins 0.000 description 1
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 1
- 206010047555 Visual field defect Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000021736 acetylation Effects 0.000 description 1
- 238000006640 acetylation reaction Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 108091000387 actin binding proteins Proteins 0.000 description 1
- 108091009126 actinin binding proteins Proteins 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 1
- 230000037444 atrophy Effects 0.000 description 1
- 230000006470 autoimmune attack Effects 0.000 description 1
- 230000005784 autoimmunity Effects 0.000 description 1
- 210000003050 axon Anatomy 0.000 description 1
- 230000031018 biological processes and functions Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 238000009530 blood pressure measurement Methods 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 230000006037 cell lysis Effects 0.000 description 1
- 230000036755 cellular response Effects 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 230000002759 chromosomal effect Effects 0.000 description 1
- 229930016911 cinnamic acid Natural products 0.000 description 1
- 235000013985 cinnamic acid Nutrition 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 238000004737 colorimetric analysis Methods 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 238000010835 comparative analysis Methods 0.000 description 1
- 238000000205 computational method Methods 0.000 description 1
- 239000013068 control sample Substances 0.000 description 1
- 239000007771 core particle Substances 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 230000003436 cytoskeletal effect Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000013501 data transformation Methods 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000001066 destructive effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 239000012470 diluted sample Substances 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 238000013399 early diagnosis Methods 0.000 description 1
- 230000001516 effect on protein Effects 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 238000003114 enzyme-linked immunosorbent spot assay Methods 0.000 description 1
- 239000003797 essential amino acid Substances 0.000 description 1
- 235000020776 essential amino acid Nutrition 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000000105 evaporative light scattering detection Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 230000004438 eyesight Effects 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 239000000834 fixative Substances 0.000 description 1
- 239000010200 folin Substances 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000009396 hybridization Methods 0.000 description 1
- 239000000017 hydrogel Substances 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 230000016784 immunoglobulin production Effects 0.000 description 1
- 229940072221 immunoglobulins Drugs 0.000 description 1
- 229940043355 kinase inhibitor Drugs 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 208000018769 loss of vision Diseases 0.000 description 1
- 231100000864 loss of vision Toxicity 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- WBYWAXJHAXSJNI-UHFFFAOYSA-N methyl p-hydroxycinnamate Natural products OC(=O)C=CC1=CC=CC=C1 WBYWAXJHAXSJNI-UHFFFAOYSA-N 0.000 description 1
- 230000011987 methylation Effects 0.000 description 1
- 238000007069 methylation reaction Methods 0.000 description 1
- 239000002105 nanoparticle Substances 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 230000008764 nerve damage Effects 0.000 description 1
- 210000005157 neural retina Anatomy 0.000 description 1
- 210000001623 nucleosome Anatomy 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 238000003909 pattern recognition Methods 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 210000001428 peripheral nervous system Anatomy 0.000 description 1
- 210000000608 photoreceptor cell Anatomy 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 238000010149 post-hoc-test Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- XJMOSONTPMZWPB-UHFFFAOYSA-M propidium iodide Chemical compound [I-].[I-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CCC[N+](C)(CC)CC)=C1C1=CC=CC=C1 XJMOSONTPMZWPB-UHFFFAOYSA-M 0.000 description 1
- 239000003909 protein kinase inhibitor Substances 0.000 description 1
- 239000012474 protein marker Substances 0.000 description 1
- 238000013138 pruning Methods 0.000 description 1
- 239000013074 reference sample Substances 0.000 description 1
- 210000001525 retina Anatomy 0.000 description 1
- 239000012723 sample buffer Substances 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 229910052710 silicon Inorganic materials 0.000 description 1
- 239000010703 silicon Substances 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- AIDBEARHLBRLMO-UHFFFAOYSA-M sodium;dodecyl sulfate;2-morpholin-4-ylethanesulfonic acid Chemical compound [Na+].OS(=O)(=O)CCN1CCOCC1.CCCCCCCCCCCCOS([O-])(=O)=O AIDBEARHLBRLMO-UHFFFAOYSA-M 0.000 description 1
- 238000000527 sonication Methods 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 238000001920 surface-enhanced laser desorption--ionisation mass spectrometry Methods 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000026676 system process Effects 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 108010019783 tear proteins Proteins 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 238000003325 tomography Methods 0.000 description 1
- 210000001585 trabecular meshwork Anatomy 0.000 description 1
- 238000012549 training Methods 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 230000004382 visual function Effects 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/16—Ophthalmology
- G01N2800/168—Glaucoma
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Hematology (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Ophthalmology & Optometry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Rehabilitation Therapy (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Rheumatology (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US34236310P | 2010-04-13 | 2010-04-13 | |
| US61/342,363 | 2010-04-13 | ||
| PCT/CH2011/000077 WO2011127616A1 (en) | 2010-04-13 | 2011-04-13 | Diagnostic methods for glaucoma |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015253808A Division JP6225157B2 (ja) | 2010-04-13 | 2015-12-25 | 緑内障の診断方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2013529292A true JP2013529292A (ja) | 2013-07-18 |
| JP2013529292A5 JP2013529292A5 (enExample) | 2014-05-29 |
Family
ID=43984128
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013504084A Pending JP2013529292A (ja) | 2010-04-13 | 2011-04-13 | 緑内障の診断方法 |
| JP2015253808A Active JP6225157B2 (ja) | 2010-04-13 | 2015-12-25 | 緑内障の診断方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015253808A Active JP6225157B2 (ja) | 2010-04-13 | 2015-12-25 | 緑内障の診断方法 |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US10175251B2 (enExample) |
| EP (1) | EP2558862B1 (enExample) |
| JP (2) | JP2013529292A (enExample) |
| KR (1) | KR101903193B1 (enExample) |
| CN (1) | CN103003693B (enExample) |
| AU (1) | AU2011241402B2 (enExample) |
| BR (1) | BR112012026219B1 (enExample) |
| CA (1) | CA2795270C (enExample) |
| DK (1) | DK2558862T3 (enExample) |
| ES (1) | ES2712060T3 (enExample) |
| HR (1) | HRP20190278T1 (enExample) |
| HU (1) | HUE042703T2 (enExample) |
| PL (1) | PL2558862T3 (enExample) |
| RU (1) | RU2657515C2 (enExample) |
| TR (1) | TR201902542T4 (enExample) |
| WO (1) | WO2011127616A1 (enExample) |
| ZA (1) | ZA201207935B (enExample) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10548472B2 (en) | 2015-05-20 | 2020-02-04 | Kabushiki Kaisha Topcon | Ophthalmic examination support system, ophthalmic examination support server and ophthalmic examination support device |
| JP2022524325A (ja) * | 2019-03-04 | 2022-05-02 | ザ スケペンス アイ リサーチ インスティテュート，インコーポレイテッド | 神経炎症の調節 |
| US12295985B2 (en) | 2011-02-28 | 2025-05-13 | The Schepens Eye Research Institute, Inc. | Methods of reducing severity of glaucoma by intravitreal administration of insulin-like growth factor binding protein-like 1 (IGFBPL1) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20140147413A1 (en) * | 2011-02-28 | 2014-05-29 | Dong Feng Chen | Therapies That Target Autoimmunity For Treating Glaucoma And Optic Neuropathy |
| US20150019136A1 (en) * | 2012-02-21 | 2015-01-15 | The Regents Of The University Of California | Systems and methods for determining retinal ganglion cell populations and associated treatments |
| ES2759026T3 (es) * | 2013-02-26 | 2020-05-07 | Inst Oftalmologico Fernandez Vega S L | Método para el diagnóstico de glaucoma basándose en la determinación de niveles de proteínas séricas |
| US20170239331A1 (en) * | 2014-10-15 | 2017-08-24 | Rapid Pathogen Screening, Inc. | Formulations for histatin protectives and therapeutics |
| RU2617066C1 (ru) * | 2016-04-01 | 2017-04-19 | Федеральное государственное автономное учреждение "Межотраслевой научно-технический комплекс "Микрохирургия глаза" имени академика С.Н. Федорова" Министерства здравоохранения Российской Федерации | Способ определения показаний к интравитреальному введению цилиарного нейротрофического фактора при лечении заболеваний зрительно-нервного аппарата глаза |
| WO2018106594A2 (en) | 2016-12-05 | 2018-06-14 | The Jackson Laboratory | Fat droplets in retina and optic nerve as a diagnostic marker for neurodegeneration and glaucoma in humans |
| JP7202609B2 (ja) * | 2017-12-13 | 2023-01-12 | 国立大学法人東北大学 | 視神経障害の診断用バイオマーカー |
| CN108229545B (zh) * | 2017-12-22 | 2021-09-14 | 北京市商汤科技开发有限公司 | 青光眼诊断的方法、装置及电子设备 |
| CN111856037B (zh) * | 2020-07-31 | 2021-06-22 | 四川大学华西第二医院 | Unc45a与hsp10的比值在pop早期预警、诊断、预后评估中的应用和产品 |
| KR102596340B1 (ko) | 2020-08-25 | 2023-11-02 | 사회복지법인 삼성생명공익재단 | 안질환 시야 손상 예후 예측 시스템 및 방법과 이를 위한 컴퓨터 프로그램 |
| CN113444789A (zh) * | 2021-08-27 | 2021-09-28 | 中国医学科学院北京协和医院 | 青光眼相关生物标志物及其应用 |
| CN114965664A (zh) * | 2022-03-21 | 2022-08-30 | 上海交通大学 | 一种获取泪液代谢指纹谱图的方法及筛选方法 |
| CN118425510B (zh) * | 2024-05-17 | 2024-11-19 | 上海市第一人民医院 | 一种青光眼诊断的生物标志物及其应用 |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2004036220A1 (en) * | 2002-10-18 | 2004-04-29 | Rescom Gmbh | Diagnosis of glaucoma by complex autoantibody repertoires in body fluids |
| JP2007514771A (ja) * | 2003-12-19 | 2007-06-07 | オメガ バイオ‐ファーマ（アイ．ピー．３）リミテッド | 糖尿病を治療するための組成物および方法 |
| WO2009077750A1 (en) * | 2007-12-14 | 2009-06-25 | Ucl Business Plc | Fluorescent marker for cell death in the eye |
| WO2009145478A2 (ko) * | 2008-04-02 | 2009-12-03 | (주)루미아이제네틱스 | 녹내장 진단용 키트 |
| JP2010507069A (ja) * | 2006-07-08 | 2010-03-04 | ユニバーシティー オブ ケンタッキー リサーチ ファンデーション | 肺癌診断アッセイ |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9419267D0 (en) | 1994-09-23 | 1994-11-09 | Unilever Plc | Assay devices |
| RU2187983C2 (ru) | 1998-11-10 | 2002-08-27 | Государственное учреждение Межотраслевой научно-технический комплекс "Микрохирургия глаза" | Способ диагностики характера течения глаукомы |
| US20020102581A1 (en) * | 1999-02-19 | 2002-08-01 | Hageman Gregory S. | Diagnostics and therapeutics for ocular disorders |
| US20030149997A1 (en) | 1999-02-19 | 2003-08-07 | Hageman Gregory S. | Diagnostics and therapeutics for arterial wall disruptive disorders |
| US7011952B2 (en) * | 2000-02-22 | 2006-03-14 | University Of Iowa Research Foundation | Diagnostics and therapeutics for macular degeneration-related disorders |
| DK2026073T3 (en) | 2000-04-29 | 2016-07-25 | Univ Iowa Res Found | Diagnosis and treatment of macular degeneration-related disorders |
| CN1393470A (zh) * | 2001-06-29 | 2003-01-29 | 上海博德基因开发有限公司 | 一种多肽——beta转导素－45.65和编码这种多肽的多核苷酸 |
| ATE526041T1 (de) * | 2001-12-11 | 2011-10-15 | Fibrogen Inc | Verfahren zur hemmung okularer vorgänge |
| CA2493849A1 (en) * | 2002-07-12 | 2004-01-22 | University Of Washington | Methods and systems for extended in vitro culture of neuronal cells |
| US7662389B2 (en) * | 2003-12-17 | 2010-02-16 | Alcon, Inc. | Use of serum amyloid A gene in diagnosis and treatment of glaucoma and identification of anti-glaucoma agents |
| AU2006272497B2 (en) * | 2005-07-27 | 2012-07-19 | University Of Florida Research Foundation, Inc. | Small compounds that correct protein misfolding and uses thereof |
| EP1832600A1 (en) * | 2006-03-09 | 2007-09-12 | Max-Delbrück-Centrum Für Molekulare Medizin | Peptides against autoantibodies associated with glaucoma and use of these peptides |
| RU2314535C1 (ru) | 2006-07-05 | 2008-01-10 | Федеральное государственное учреждение "Межотраслевой научно-технический комплекс "Микрохирургия глаза" имени академика С.Н. Федорова Федерального агентства по здравоохранению и социальному развитию" | Способ диагностики начальной стадии открытоугольной глаукомы |
| EP1929937A1 (de) * | 2006-12-07 | 2008-06-11 | F. Hoffmann-Roche AG | Vorrichtung und Verfahren zum Untersuchen von Körperflüssigkeiten |
| RU2371721C2 (ru) | 2007-06-25 | 2009-10-27 | Закрытое акционерное общество "Молекулярно-медицинские технологии" | Устройство для диагностики с использованием биочипов |
| EP2354792A1 (en) | 2010-02-08 | 2011-08-10 | Biomonitor A/S | Method for detecting anti-drug antibodies |
| KR20100087276A (ko) | 2010-07-21 | 2010-08-04 | (주)루미아이제네틱스 | 녹내장 진단용 키트 |
| KR20100087275A (ko) | 2010-07-21 | 2010-08-04 | (주)루미아이제네틱스 | 녹내장 진단용 키트 |
-
2011
- 2011-04-13 BR BR112012026219A patent/BR112012026219B1/pt active IP Right Grant
- 2011-04-13 AU AU2011241402A patent/AU2011241402B2/en active Active
- 2011-04-13 ES ES11714916T patent/ES2712060T3/es active Active
- 2011-04-13 CA CA2795270A patent/CA2795270C/en active Active
- 2011-04-13 HU HUE11714916A patent/HUE042703T2/hu unknown
- 2011-04-13 EP EP11714916.1A patent/EP2558862B1/en active Active
- 2011-04-13 DK DK11714916.1T patent/DK2558862T3/en active
- 2011-04-13 PL PL11714916T patent/PL2558862T3/pl unknown
- 2011-04-13 RU RU2012147551A patent/RU2657515C2/ru active
- 2011-04-13 TR TR2019/02542T patent/TR201902542T4/tr unknown
- 2011-04-13 WO PCT/CH2011/000077 patent/WO2011127616A1/en not_active Ceased
- 2011-04-13 KR KR1020127029751A patent/KR101903193B1/ko active Active
- 2011-04-13 HR HRP20190278TT patent/HRP20190278T1/hr unknown
- 2011-04-13 JP JP2013504084A patent/JP2013529292A/ja active Pending
- 2011-04-13 US US13/641,009 patent/US10175251B2/en active Active
- 2011-04-13 CN CN201180028608.XA patent/CN103003693B/zh active Active
-
2012
- 2012-10-22 ZA ZA2012/07935A patent/ZA201207935B/en unknown
-
2015
- 2015-12-25 JP JP2015253808A patent/JP6225157B2/ja active Active
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2004036220A1 (en) * | 2002-10-18 | 2004-04-29 | Rescom Gmbh | Diagnosis of glaucoma by complex autoantibody repertoires in body fluids |
| JP2007514771A (ja) * | 2003-12-19 | 2007-06-07 | オメガ バイオ‐ファーマ（アイ．ピー．３）リミテッド | 糖尿病を治療するための組成物および方法 |
| JP2010507069A (ja) * | 2006-07-08 | 2010-03-04 | ユニバーシティー オブ ケンタッキー リサーチ ファンデーション | 肺癌診断アッセイ |
| WO2009077750A1 (en) * | 2007-12-14 | 2009-06-25 | Ucl Business Plc | Fluorescent marker for cell death in the eye |
| WO2009145478A2 (ko) * | 2008-04-02 | 2009-12-03 | (주)루미아이제네틱스 | 녹내장 진단용 키트 |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12295985B2 (en) | 2011-02-28 | 2025-05-13 | The Schepens Eye Research Institute, Inc. | Methods of reducing severity of glaucoma by intravitreal administration of insulin-like growth factor binding protein-like 1 (IGFBPL1) |
| US10548472B2 (en) | 2015-05-20 | 2020-02-04 | Kabushiki Kaisha Topcon | Ophthalmic examination support system, ophthalmic examination support server and ophthalmic examination support device |
| JP2022524325A (ja) * | 2019-03-04 | 2022-05-02 | ザ スケペンス アイ リサーチ インスティテュート，インコーポレイテッド | 神経炎症の調節 |
| JP7738377B2 (ja) | 2019-03-04 | 2025-09-12 | マサチューセッツ アイ アンド イヤー インファーマリー | 神経炎症の調節 |
Also Published As
| Publication number | Publication date |
|---|---|
| BR112012026219B1 (pt) | 2019-12-10 |
| DK2558862T3 (en) | 2019-03-18 |
| PL2558862T3 (pl) | 2019-07-31 |
| HRP20190278T1 (hr) | 2019-04-19 |
| AU2011241402A1 (en) | 2012-11-15 |
| BR112012026219A2 (pt) | 2016-07-12 |
| AU2011241402B2 (en) | 2016-09-15 |
| WO2011127616A1 (en) | 2011-10-20 |
| US20130172204A1 (en) | 2013-07-04 |
| CN103003693B (zh) | 2016-07-06 |
| EP2558862B1 (en) | 2018-11-21 |
| ES2712060T3 (es) | 2019-05-09 |
| ZA201207935B (en) | 2019-07-31 |
| EP2558862A1 (en) | 2013-02-20 |
| TR201902542T4 (tr) | 2019-03-21 |
| RU2012147551A (ru) | 2014-05-20 |
| KR101903193B1 (ko) | 2018-10-01 |
| JP2016048265A (ja) | 2016-04-07 |
| KR20130122706A (ko) | 2013-11-08 |
| CA2795270C (en) | 2021-06-08 |
| US10175251B2 (en) | 2019-01-08 |
| CA2795270A1 (en) | 2011-10-20 |
| RU2657515C2 (ru) | 2018-06-14 |
| CN103003693A (zh) | 2013-03-27 |
| HUE042703T2 (hu) | 2019-07-29 |
| JP6225157B2 (ja) | 2017-11-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6225157B2 (ja) | 緑内障の診断方法 | |
| US20230393133A1 (en) | Blood biomarker that predicts persistent cognitive dysfunction after concussion | |
| EP2657706B1 (en) | Biomarker for cognitive dysfunction diseases, and method for detection of cognitive dysfunction diseases using the biomarker | |
| JP2013529292A5 (enExample) | ||
| EP2444814B9 (en) | Biomarker for mental disorders including cognitive disorders, and method using said biomarker to detect mental disorders including cognitive disorders | |
| CN108431608A (zh) | 用于诊断或预后阿尔茨海默病或用于诊断帕金森病的乳铁蛋白 | |
| US9977036B2 (en) | Diagnostic markers for multiple sclerosis | |
| RU2741227C1 (ru) | Способ диагностики черепно-мозговой травмы с использованием белковых биомаркеров |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20140409 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20140409 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20141008 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20141014 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20150113 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20150210 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20150414 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20150901 |